Αποτελέσματα Αναζήτησης
• RZV was found cost-saving in several immune-compromised populations. ... . 68 The authors further noted that cost-effectiveness models should be updated when new evidence becomes available to support the effect on a potential vaccination ... Cost-effectiveness of Herpes Zoster vaccine for persons aged 50 years. Ann Intern Med. 2015;163(7 ...
- Insights into the Novel Therapeutics and Vaccines against Herpes ...
Live-attenuated vaccination has also contributed to the...
- Cost-effectiveness of herpes zoster vaccines in the U.S.: A systematic ...
All studies incorporated health system costs. Ten out of...
- Insights into the Novel Therapeutics and Vaccines against Herpes ...
25 Ιουλ 2024 · The vaccine should be cost–effective and price should not be a barrier to access, including in LMICs. Dosage, regimen, and cost of goods should be amenable to affordable supply.
Live-attenuated vaccination has also contributed to the development of FDA-approved oncolytic virotherapy against herpes simplex virus known as (TVEC or Imlygic), which limits virus replication and regulates human immunity, and which is used for treating human melanoma .
22 Ιουλ 2022 · All studies incorporated health system costs. Ten out of eleven (90.9%) studies conducted their analyses from a societal perspective and included indirect costs.
14 Μαρ 2023 · What is the impact?•. The overview of the currently available body of evidence related to cost-effectiveness of RZV may help informing decision makers about the value of vaccination against herpes zoster. Publication types. Review. Research Support, Non-U.S. Gov't. MeSH terms. Cost-Benefit Analysis. Herpes Zoster Vaccine*
6 Δεκ 2021 · Development of the therapeutic Shingrix vaccine for Herpes Zoster and a prophylactic vaccine for varicella zoster virus (VZV) has increased efforts for HSV vaccine due to similarities between the two viruses, especially with the establishment of latency (Heineman et al., 2019).
4 Ιαν 2023 · Individuals who are IC due to disease or immunosuppressive therapy are at increased risk of HZ and associated complications. There is a developing body of literature on HZ vaccination in IC adults and available data suggest there is a favorable benefit-risk profile for RZV in a broad range of IC populations.
